AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Breast cancer: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)NCT03036488 · results posted 2026-10-22 · Merck Sharp & Dohme LLC · 1174 people · tests Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · results posted 2026-09-29 · Seagen, a wholly owned subsidiary of Pfizer · 654 people · tests Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerNCT01547741 · results posted 2026-08-06 · NSABP Foundation Inc · 4242 people · tests Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantNCT03439046 · results posted 2026-07-10 · Novartis Pharmaceuticals · 287 people · tests Ribociclib, Letrozole, Alpelisib, Fulvestrant MRI and Mammography Before Surgery in Patients With Stage I-II Breast CancerNCT01805076 · results posted 2026-06-26 · Alliance for Clinical Trials in Oncology · 319 people · tests Breast surgery, Magnetic resonance imaging, Mammography Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerNCT05113251 · results posted 2026-06-09 · AstraZeneca · 927 people · tests Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel HypersensitivityNCT03598426 · results posted 2026-06-09 · Loma Linda University · 90 people · tests Dexamethasone Prospective Randomized Study of Accelerated Radiation Therapy (PRART)NCT04175210 · results posted 2026-05-07 · Weill Medical College of Cornell University · 397 people · tests Radiation therapy - 3 weeks, Radiation therapy - 2 weeks Evaluation in the Treatment of Neuropathic Pain Post Breast SurgeryNCT03794388 · results posted 2026-05-05 · Institut Cancerologie de l'Ouest · 140 people · tests Capsaicin, Pregabalin Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerNCT03414970 · results posted 2026-02-24 · Alliance for Clinical Trials in Oncology · 898 people · tests Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory B… Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerNCT02947685 · results posted 2026-02-12 · Alliance Foundation Trials, LLC. · 518 people · tests palbociclib, trastuzumab, pertuzumab, letrozole A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)NCT05104866 · results posted 2026-02-04 · AstraZeneca · 732 people · tests Dato-DXd, Capecitabine, Gemcitabine, Eribulin
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.Nat Med 2026 · PMID 42926233 Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136 Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.Ann Oncol 2026 · PMID 42926111 Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinas…Ann Oncol 2026 · PMID 42926110 Adjuvant chemotherapy with cisplatin and gemcitabine compared to standard of care after curative intent resection of cholangiocarcinoma and…Ann Oncol 2026 · PMID 42926109 Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanc…Ann Oncol 2026 · PMID 42926108 A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil wi…Ann Oncol 2026 · PMID 42926107 Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient me…Ann Oncol 2026 · PMID 42926106 Optimising late-line treatment administration in metastatic colorectal cancer: an even brighter SUNLIGHT.Lancet 2026 · PMID 42925881 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicent…Lancet 2026 · PMID 42925880 Q&A: Dan Landau on Somatic Evolution.Cancer Discov 2026 · PMID 42924526 ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Local…J Clin Oncol 2026 · PMID 42921729
🏛️

US drug labels updated

A label changes when a new use, dose or warning is approved · openFDA

No label updates found.

An update is not always a new approval — open the label to see what changed.

Some sources did not answer: openFDA answered 500

Want these every week? Follow breast cancer and get a note on your phone with the new trials and papers.

🔔 Follow breast cancer
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy